←
Ivelin Georgiev, Ph.D.272 posts
Ivelin Georgiev, Ph.D. avatar

Ivelin Georgiev, Ph.D.

@IG_lab

Georgiev Lab at Vanderbilt, focusing on computational immunology and vaccine research.

◷ Joined December 2016▧ 26 Photos and videos
Kelsey Voss avatar
⟳ Ivelin Georgiev, Ph.D. retweeted
Kelsey Voss@DoctorKvoss·31 Dec 2025

Check out this exciting collaboration with @IG_lab now available as a preprint- Development and application of nbLIBRA-seq for high-throughput discovery of antigen-specific nanobodies biorxiv.org/content/10.64898… So fun to take this risk and watch it succeed. 🍾

Andy Kilianski avatar
⟳ Ivelin Georgiev, Ph.D. retweeted
Andy Kilianski@AndyKilianski·5 Nov 2025

Great work by @IG_lab and @VUMCDiscoveries on open-source AI tools for de novo biologics design and development. MAGE paves the way for target-agnostic mAb tools for all disease. Excited to be a part of it @ARPA_H - AI biodesign tools for everyone! cell.com/cell/fulltext/S0092…

Vanderbilt University Medical Center avatar
⟳ Ivelin Georgiev, Ph.D. retweeted
Vanderbilt University Medical Center@VUMCDiscoveries·13 Mar 2025

An ambitious project led by @VUMChealth investigators aims to use #AI technologies to generate antibody therapies against any antigen target of interest. @IG_lab will serve as the project principal investigator. news.vumc.org/2025/03/10/vum…

Ivelin Georgiev, Ph.D. avatar
Ivelin Georgiev, Ph.D.@IG_lab·3 Mar 2025

Using #antibody sequence alone, can we predict whether two antibodies target overlapping epitopes? A new suite of algorithms developed by @ClintVaccine: Contrastive Learning Enables Epitope Overlap Predictions for Targeted Antibody Discovery biorxiv.org/content/10.1101/…

vaccine_clint avatar
⟳ Ivelin Georgiev, Ph.D. retweeted
vaccine_clint@ClintVaccine·23 Dec 2024

Happy to be part of a disruptive project out of my lab. Essentially #ChatGPTForAntibodies — feed in an antigen sequence and it returns an antibody sequence that has a high probability of binding.

Monoclonal antibodies are crucial in medicine and research, but their discovery is slow, costly, and complex. What if #AI could change this - creating fully human #antibodies, on demand, for a target of interest? The magic is in #MAGE: biorxiv.org/content/10.1101/…

Ivelin Georgiev, Ph.D. avatar
Ivelin Georgiev, Ph.D.@IG_lab·23 Dec 2024

A few highlights of MAGE (Monoclonal Antibody GEnerator): 1. Input is only #antigen (target) sequence, no structures or models needed. 2. Output is fully human paired heavy-light chain #antibodies. 3. MAGE was validated to work for known or related targets, with high hit rates.

Ivelin Georgiev, Ph.D. avatar
Ivelin Georgiev, Ph.D.@IG_lab·23 Dec 2024

Monoclonal antibodies are crucial in medicine and research, but their discovery is slow, costly, and complex. What if #AI could change this - creating fully human #antibodies, on demand, for a target of interest? The magic is in #MAGE: biorxiv.org/content/10.1101/…

Biology+AI Daily avatar
⟳ Ivelin Georgiev, Ph.D. retweeted
Biology+AI Daily@BiologyAIDaily·23 Dec 2024

Generation of antigen-specific paired heavy-light chain antibody sequences using large language models 1. The study introduces MAGE, a groundbreaking protein large language model (LLM) designed to generate antigen-specific paired heavy and light chain antibody sequences, showcasing the potential of AI in revolutionizing antibody discovery. 2. MAGE uniquely eliminates the need for pre-existing antibody templates or structural information, relying solely on antigen sequences to produce functional and novel antibody designs with experimental validation. 3. Validation experiments highlight MAGE's ability to create diverse antibodies against critical targets like SARS-CoV-2, H5N1 avian influenza, and RSV-A, demonstrating its versatility and broad applicability. 4. A standout achievement includes zero-shot learning capabilities, where MAGE generated effective antibodies for the unseen H5N1 variant, proving its value in addressing emerging health threats rapidly. 5. Structural analyses reveal that MAGE-designed antibodies bind to distinct epitopes, showcasing novel binding modes and demonstrating their potential for therapeutic application. 6. The study underlines MAGE's ability to design antibodies with potent neutralization capabilities, such as against SARS-CoV-2 variants, including Omicron, indicating its relevance in vaccine and therapeutic development. 7. By leveraging a curated dataset and advanced machine learning techniques, MAGE achieves high novelty and diversity in its antibody sequences, expanding the possibilities for antibody engineering. 8. The research emphasizes that MAGE can significantly accelerate antibody discovery processes, overcoming traditional bottlenecks like inefficiency, high costs, and long timelines. 9. Future applications of MAGE promise to extend beyond virology, potentially transforming fields like oncology and autoimmune disease treatment with AI-driven antibody generation. @IG_lab @McLellan_Lab @DannySheward @HelenChuMD 📜Paper: biorxiv.org/content/10.1101/… #AI #AntibodyDiscovery #Bioinformatics #ProteinDesign #MachineLearning

Post attachment